DIL
BBIO icon

Deeter Investments LLP’s BridgeBio Pharma BBIO Stock Holding History

Deeter Investments LLP’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.35M Buy
+83,000
New +$5.45M 1.36% 24

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deeter Investments LLP's BBIO Position: Q4 2025 in Review

Deeter Investments LLP opened a new position in BridgeBio Pharma (BBIO) in Q4 2025: 83,000 shares worth $6.35M. The stake represents 1.36% of the portfolio and ranks #24 among its holdings.

434 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Deeter Investments LLP held 83,000 shares of BridgeBio Pharma worth $6.35M as of Q4 2025.
  • BridgeBio Pharma was a new Deeter Investments LLP position in Q4 2025.
  • BridgeBio Pharma made up 1.36% of Deeter Investments LLP's portfolio in Q4 2025, its #24 holding.
  • 434 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Deeter Investments LLP's 13F filing for Q4 2025, filed 28 Aug 2026.